Soluble CD163, a Specific Macrophage Activation Marker, is Decreased by Anti-TNF-α Antibody Treatment in Active Inflammatory Bowel Disease

Scandinavian Journal of Immunology

Volumn 80, Issue 6, 2014, Pages 417-423

  Dige, A ^a,b   Stoy S ^a   Thomsen, K L ^a   Hvas, C L ^a   Agnholt, J ^a   Dahlerup, J F ^a   Moller H J ^a   Gronbaek H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HORSENS REGIONAL HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD14 ANTIGEN; CD163 ANTIGEN; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; FOLLOW UP; HUMAN; HUMAN CELL; INFLAMMATORY BOWEL DISEASE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; COLITIS, ULCERATIVE; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MACROPHAGE; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MACROPHAGE ACTIVATION; MACROPHAGES; MONOCYTES; RECEPTORS, CELL SURFACE; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922540656     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12222     Document Type: Article

References (33)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006;3:390-407.
3. Demetter P, De VM, Van Huysse JA et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis 2005;64:321-4.
4. Franze E, Caruso R, Stolfi C et al. Lesional Accumulation of CD163-Expressing Cells in the Gut of Patients with Inflammatory Bowel Disease. PLoS One 2013;8:e69839.
5. Kamada N, Hisamatsu T, Okamoto S et al. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008;118:2269-80.
6. Kamada N, Hisamatsu T, Honda H et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010;16:568-75.
7. Uo M, Hisamatsu T, Miyoshi J et al. Mucosal CXCR4 + IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcgammaR-mediated CD14 macrophage activation. Gut 2013;62:1734-44.
8. Thiesen S, Janciauskiene S, Uronen-Hansson H et al. CD14hiHLA-DRdim macrophages, with a resemblance to classical blood monocytes, dominate inflamed mucosa in Crohn's disease. J Leukoc Biol 2014;95:531-41.
9. Smith AM, Rahman FZ, Hayee B et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J Exp Med 2009;206:1883-97.
10. Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201.
11. Davis BH, Zarev PV. Human monocyte CD163 expression inversely correlates with soluble CD163 plasma levels. Cytometry B Clin Cytom 2005;63:16-22.
12. Moller HJ. Soluble CD163. Scand J Clin Lab Invest 2012;72:1-13.
13. Hiraoka A, Horiike N, Akbar SM et al. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 2005;40:52-6.
14. Fabriek BO, Moller HJ, Vloet RP et al. Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol 2007;187:179-86.
15. Bleesing J, Prada A, Siegel DM et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:965-71.
16. Moller HJ, Gronbaek H, Schiodt FV et al. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 2007;47:671-6.
17. Baeten D, Moller HJ, Delanghe J et al. Association of CD163 + macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004;50:1611-23.
18. Greisen SR, Moller HJ, Stengaard-Pedersen K et al. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis. Clin Exp Rheumatol 2011;29:689-92.
19. Moller HJ, Aerts H, Gronbaek H et al. Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Invest Suppl 2002;237:29-33.
20. Denmark VK, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Rev Clin Immunol 2013;9:77-92.
21. Lugering A, Schmidt M, Lugering N et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
22. Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005;21:251-8.
23. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
24. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955;2:1041-8.
25. Dige A, Hvas CL, Kelsen J et al. Ethylene-Diamine-Tetra-Acetate (EDTA) mimics the effect of regulatory T cells in suppression assays: a potential pitfall when using AutoMACS-separated cells. J Immunol Methods 2010;353:141-4.
26. Dige A, Hvas CL, Deleuran B et al. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells. Scand J Gastroenterol 2011;46:1206-14.
27. Hvas CL, Kelsen J, Agnholt J et al. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease. Autoimmunity 2010;43:325-33.
28. Moller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest 2002;62:293-9.
29. Van den Heuvel MM, Tensen CP, van As JH et al. Regulation of CD 163 on human macrophages: cross-linking of CD163 induces signaling and activation. J Leukoc Biol 1999;66:858-66.
30. Hogger P, Dreier J, Droste A, Buck F, Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998;161:1883-90.
31. Sulahian TH, Hogger P, Wahner AE et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000;12:1312-21.
32. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
33. Papay P, Ignjatovic A, Karmiris K et al. Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis 2013;7:653-69.